Elutia Inc. to Post FY2024 Earnings of ($1.37) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:ELUT)

Elutia Inc. (NASDAQ:ELUT) – Cantor Fitzgerald increased their FY2024 EPS estimates for shares of Elutia in a research note issued on Thursday, June 20th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.37) per share for the year, up from their prior estimate of ($1.38). Cantor Fitzgerald has a “Overweight” rating and a $11.00 price objective on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.38) per share.

Elutia (NASDAQ:ELUT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) EPS for the quarter. The business had revenue of $6.69 million for the quarter.

Separately, Lake Street Capital increased their price objective on shares of Elutia from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday.

Elutia Trading Up 0.6 %

ELUT stock opened at $3.50 on Monday. The company has a market cap of $84.95 million, a price-to-earnings ratio of -1.48 and a beta of 0.61. Elutia has a 12 month low of $1.10 and a 12 month high of $4.39. The firm has a 50-day moving average of $3.20 and a two-hundred day moving average of $3.16.

Institutional Trading of Elutia

An institutional investor recently bought a new position in Elutia stock. Verdence Capital Advisors LLC purchased a new stake in Elutia Inc. (NASDAQ:ELUT) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 14,410 shares of the company’s stock, valued at approximately $45,000. Verdence Capital Advisors LLC owned 0.06% of Elutia at the end of the most recent reporting period. Institutional investors own 74.03% of the company’s stock.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.